
DNA damage response biotech launches with £25m funding
pharmafile | September 22, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | biotech, dna damage response, funding
Cambridge-based Artios Pharma has officially launched after raising £25 million in series A financing from US and European life science investors.
Funding was led by a number of investors including AbbVie Ventures and SV Life Sciences with participation from Merck Ventures.
The biotech was formed from assets out of Cancer Research UK’s technology transfer unit and will use this new investment to focus on the development of a pipeline of DNA damage response (DDR) cancer therapies.
The company is led by CEO Dr Niall Martin, who brings “proven expertise” in DDR drug discovery to the role.
Artios said it is actively building a pipeline of “highly promising” first-in-class DDR therapies identified from a global network of leading researchers in the DDR field, in a statement at the London Stock Exchange.
Matt Fellows
Related Content

Antiverse receive investment from IIC and Development Bank of Wales
As part of its $9.3m Series A funding round, Antiverse has received a joint equity …

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …

Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …






